228. 閉塞性細気管支炎 Disease details / Clinical trials / Drug dev / DR info

5-methyl-1-phenyl-2-1-(H)-pyridone
   Clinical Trials Unit, Rigshospitalet
      2015   Phase 2   EUCTR2014-002022-12-SE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-NL   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-GB   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-BE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DK   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
Aerolised liposomal ciclosporin A
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Aerolised liposomal ciclosporin A 10MG
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
Aerolised liposomal ciclosporin A 5MG
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
Arina-1
   Renovion, Inc.
      2023   Phase 3   NCT05654922   United States
Azithromycin
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT01959100   France
   Dana-Farber Cancer Institute
      2024   Phase 2   NCT05922761   United States
   Hospital Authority, Hong Kong
      2005   -   NCT00563251   China
   KULeuven and University Hospitals Leuven
      2013   Phase 4   EUCTR2012-003331-32-BE   Belgium
   Katholieke Universiteit Leuven
      2005   Phase 4   NCT01009619   Belgium
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
   Newcastle upon Tyne Hospitals NHS Trust
      2006   -   EUCTR2006-000485-36-GB   United Kingdom
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States
Azithromycin + N-acetylcystein + inhaled corticosteroid
   Asan Medical Center
      2011   -   NCT01327625   Korea, Republic of
Azithromycin dihydrate
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium
      2009   Phase 4   EUCTR2005-003893-46-BE   Belgium
Azithromycine 250 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   Phase 3   EUCTR2013-000499-14-FR   France
AZM
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China
Aztreonam
   Duke University
      2013   Phase 4   NCT01469364   United States
Basiliximab
   University Health Network, Toronto
      2004   Phase 3   NCT00188825   Canada
Belumosudil
   Dana-Farber Cancer Institute
      2024   Phase 2   NCT05922761   United States
Bortezomib
   Northwestern University
      2010   Phase 2   NCT01163786   United States
Budesonide/formoterol
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT01560689   France
Certican
   St Vincent's Hospital
      2005   -   EUCTR2004-001290-25-GB   Austria;Germany;Spain;United Kingdom
Certican 0,5 MG tabletten
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
Certican 0,75MG tabletten
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
Ciclosporin A
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-FR   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain
   ZAMBON SpA
      2021   Phase 3   EUCTR2018-003204-39-BE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-DE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Zambon SpA
      2023   Phase 3   EUCTR2019-002987-29-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-BE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
Ciclosporina / ciclosporin
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Ciclosporina A liposomica aerolised liposomal ciclosporin A
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Ciclosporina/ ciclosporin
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Ciclosporine A
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom
Ciclosporine, ciclosporina
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Clarithromycin
   Baqiyatallah Medical Sciences University
      2003   Phase 3   NCT00381147   Iran, Islamic Republic of
Colecalciferol
   UZ Gasthuisberg
      2010   -   EUCTR2010-022027-30-BE   Belgium
Cyclosporine
   Universitätsklinikum Hamburg-Eppendorf
      2001   Phase 3   NCT01429844   Australia;Austria;Belgium;Germany;Spain;Switzerland
Cyclosporine A
   University Medical Centre Groningen
      2007   Phase 0   NCT00378677   Netherlands
Cyclosporine inhalation solution
   APT Pharmaceuticals, Inc.
      2008   Phase 3   NCT00755781   Canada;United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 2   NCT01273207   United States
      2011   Phase 2   NCT01287078   United States
   Pari Pharma GmbH
      2009   Phase 2/Phase 3   NCT01334892   Germany
D-cure
   UZ Gasthuisberg
      2010   -   EUCTR2010-022027-30-BE   Belgium
EIT
   Guy's and St Thomas' NHS Foundation Trust
      2016   -   NCT02863835   United Kingdom
Enteric coated mycophenolate sodium
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom
ERL080
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom
Erythromycin
   Baqiyatallah Medical Sciences University
      2006   Phase 4   NCT00367419   Iran, Islamic Republic of
Esbriet
   Clinical Trials Unit, Rigshospitalet
      2015   Phase 2   EUCTR2014-002022-12-SE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-NL   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-GB   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-BE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DK   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
   Stanford University
      2018   Phase 1   NCT03315741   United States
Etanercept
   FDA Office of Orphan Products Development
      2001   Phase 1/Phase 2   NCT00029328   United States
   University of Michigan Cancer Center
      2003   Phase 2   NCT00141726   United States
Everolimus
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom
FAM therapy
   Ann & Robert H Lurie Children's Hospital of Chicago
      2015   -   NCT03072849   United States
Fluticasone
   Dana-Farber Cancer Institute
      2024   Phase 2   NCT05922761   United States
Fluticasone propionate
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States
Formoterol/budesonide
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00624754   France
Glucocorticoid
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China
HP 129xenon
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 1/Phase 2   NCT03603899   United States
Hyperpolarized helium-3 MRI
   Children's Hospital Medical Center, Cincinnati
      2014   -   NCT02316392   United States
Imukin
   Freistaat Bayern
      -   -   EUCTR2010-022467-36-DE   Germany
INCB039110
   Incyte Corporation
      2020   Phase 1;Phase 2   EUCTR2019-004171-39-BE   Belgium;Canada;United States
Inhalation
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain
   Duke University
      2013   Phase 4   NCT01469364   United States
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2012   Phase 3   NCT01439958   Germany
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
   University Medical Centre Groningen
      2007   Phase 0   NCT00378677   Netherlands
   Zambon SpA
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain
Inhaled hyperpolarized xenon-129
   Hamilton Health Sciences Corporation
      2019   -   NCT04029636   Canada
Interferon gamma 1B
   University Hospital Regensburg
      2012   Phase 2   NCT01639261   Germany
Interferon gamma-1B
   Freistaat Bayern
      -   -   EUCTR2010-022467-36-DE   Germany
Itacitinib
   Incyte Corporation
      2021   Phase 2   NCT04640025   Austria;Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United States
      2020   Phase 1/Phase 2   NCT03978637   Belgium;Canada;United States
Itacitinib adipate
   Incyte Corporation
      2020   Phase 1;Phase 2   EUCTR2019-004171-39-BE   Belgium;Canada;United States
   M.D. Anderson Cancer Center
      2021   Phase 1   NCT04239989   United States
L-CSA
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-FR   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
   ZAMBON SpA
      2021   Phase 3   EUCTR2018-003204-39-BE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-DE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Zambon SpA
      2023   Phase 3   EUCTR2019-002987-29-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2019-002987-29-BE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-BE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
Lactose
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00624754   France
LAM-001
   Steven Hays, MD
      2023   Phase 2   NCT06018766   United States
Liposomal aerosol cyclosporine
   University of Maryland, College Park
      2012   Phase 1/Phase 2   NCT01650545   United States
Liposomal cyclosporine A
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-FR   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain
   ZAMBON SpA
      2021   Phase 3   EUCTR2018-003204-39-BE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003204-39-DE   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
   Zambon SpA
      2023   Phase 3   EUCTR2019-002987-29-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2019-002987-29-BE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 2   NCT04107675   France;Germany;Spain
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   NCT03657342   Belgium;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   NCT03656926   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-BE   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
Liposomal cyclosporine A 10 MG
   Zambon SpA
      2020   Phase 3   NCT04039347   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
Liposomal cyclosporine A 5 MG
   Zambon SpA
      2020   Phase 3   NCT04039347   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States
Lysine
   Duke University
      2013   Phase 4   NCT01469364   United States
Mesenchymal stem cell 0.5
   Mayo Clinic
      2014   Phase 1   NCT02181712   United States
Mesenchymal stem cell 1.0
   Mayo Clinic
      2014   Phase 1   NCT02181712   United States
Montelukast
   Dana-Farber Cancer Institute
      2024   Phase 2   NCT05922761   United States
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
   Universitaire Ziekenhuizen Leuven
      2010   Phase 4   NCT01211509   Belgium
Montelukast sodium
   National Cancer Institute (NCI)
      2008   Phase 2   NCT00656058   United States
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States
   UZ Gasthuisberg
      2010   -   EUCTR2010-021983-14-BE   Belgium
Montelukast teva
   UZ Gasthuisberg
      2010   -   EUCTR2010-021983-14-BE   Belgium
MPH966
   National Cancer Institute (NCI)
      2016   Phase 1/Phase 2   NCT02669251   United States
Mscs
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China
Mycophenolate
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
Myfortic
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
   St Vincent's Hospital
      2005   -   EUCTR2004-001290-25-GB   Austria;Germany;Spain;United Kingdom
Nintedanib
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2019   Phase 3   EUCTR2018-001747-31-FR   France
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 3   NCT03283007   France
   University Hospital, Basel, Switzerland
      2019   Phase 2   NCT03805477   Austria;Germany;Saudi Arabia;Switzerland
Ofev
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2019   Phase 3   EUCTR2018-001747-31-FR   France
Other sources
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium
Pirfenidone
   Clinical Trials Unit, Rigshospitalet
      2015   Phase 2   EUCTR2014-002022-12-SE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-NL   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-GB   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-002022-12-BE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DK   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
      2014   Phase 2   EUCTR2014-002022-12-DE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom
   Rigshospitalet, Denmark
      2015   Phase 2/Phase 3   NCT02262299   Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom
   Stanford University
      2018   Phase 1   NCT03315741   United States
Prednisone
   Dana-Farber Cancer Institute
      2024   Phase 2   NCT05922761   United States
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
Pulmonary function testing
   Ann & Robert H Lurie Children's Hospital of Chicago
      2015   -   NCT03072849   United States
RAD001
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom
Ruxolitinib
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT04908735   United States
   First Affiliated Hospital of Zhejiang University
      2022   Phase 2   NCT05413356   China
   Massachusetts General Hospital
      2019   Phase 2   NCT03674047   United States
Salbutamol
   Rambam Health Care Campus
      2023   -   NCT05932316   Israel
Salbutamol nebulisation and with cpap
   Guy's and St Thomas' NHS Foundation Trust
      2016   -   NCT02863835   United Kingdom
Seretide
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04655508   France
Singulair
   National Cancer Institute (NCI)
      2008   Phase 2   NCT00656058   United States
   UZ Gasthuisberg
      2010   -   EUCTR2010-021983-14-BE   Belgium
Sodium chloride solution
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Sodium chloride solvent
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Solucion DE cloruro DE sodio sodium chloride solution
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Solvente cloruro DE sodio sodium chloride solvent
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Solvente DE cloruro DE sodio
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom
Spirometry
   Rambam Health Care Campus
      2023   -   NCT05932316   Israel
Standard immune suppression, oral
   University of Maryland, College Park
      2012   Phase 1/Phase 2   NCT01650545   United States
Standard OF care only
   Renovion, Inc.
      2023   Phase 3   NCT05654922   United States
Status post lung transplant
   Duke University
      2013   Phase 4   NCT01469364   United States
Symbicort
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
Tacrolimus
   Universitätsklinikum Hamburg-Eppendorf
      2001   Phase 3   NCT01429844   Australia;Austria;Belgium;Germany;Spain;Switzerland
Vitamin D
   Universitaire Ziekenhuizen Leuven
      2010   Phase 4   NCT01212406   Belgium
Zithromax
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2009   Phase 4   EUCTR2005-003893-46-BE   Belgium
Zitromax
   KULeuven and University Hospitals Leuven
      2013   Phase 4   EUCTR2012-003331-32-BE   Belgium
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium